

Res. Asst. PhD Elif BİLGİN DOĞRU

Personal Information

Office Phone: [+90 212 414 2434](tel:+902124142434)

Web: <http://aves.istanbul.edu.tr/elif.bilgin/>

Address: İstanbul Üniversitesi Onkoloji Enstitüsü Biyokimya Lab. Kat:3 Çapa/Fatih

International Researcher IDs

ORCID: 0000-0003-0077-7939

Publons / Web Of Science ResearcherID: A-6543-2018

Yoksis Researcher ID: 36679

Education Information

Undergraduate, İstanbul University, Open And Distance Education Faculty, Open Education Programs, Turkey 2022 - Continues

Doctorate, İstanbul University, Health Sciences Institute, Temel Onkoloji Anabilim Dalı/Kanser Biyokimyası Programı, Turkey 2013 - 2021

Postgraduate, İstanbul University, Health Sciences Institute, Temel Onkoloji Anabilim Dalı/Kanser Biyokimyası Programı, Turkey 2010 - 2013

Undergraduate, İstanbul University, Mühendislik Fakültesi, Kimya, Turkey 2005 - 2010

Foreign Languages

German, C1 Advanced

French, B1 Intermediate

English, C1 Advanced

Certificates, Courses and Trainings

Vocational Training, Wiley dergilerinde başarıyla akademik makale yayımlayabilmek: Editörümüzden bazı önemli detaylar, Wiley, 2023

Health&Medicine, VIII. Onkolojide Araştırma Uygulamaları Kursu - Kanseri İmmün Hedefleme, Dokuz Eylül Üniversitesi, 2023

Health&Medicine, İlkyardım Eğitimi, İstanbul Üniversitesi, 2023

Vocational Training, Eğiticinin Eğitimi, İstanbul Üniversitesi, 2023

Health&Medicine, EFT Uygulayıcı Eğitimi, Haliç Üniversitesi, 2019

Health&Medicine, Bioenerji Uygulayıcı Eğitimi, Haliç Üniversitesi, 2019

Health&Medicine, DNA Hasarı, Onarımı ve Tandem Kütle Spektrometrik Değerlendirilmesi, Dokuz Eylül Üniversitesi, 2018

Health&Medicine, Yeni Nesil Dizi Analizi ve Onkolojide Kullanım Alanları Kursu, Temel Onkoloji Derneği, 2018

Health&Medicine, Kök Hücrede Uygulamalı Flow Sitometri Eğitimi, Kocaeli Üniversitesi, 2018

Health&Medicine, XXIV. Kök Hücre ve Doku Mühendisliği Kursu: Temel Kök Hücre Teknikleri ve Moleküler Biyoloji Uygulamaları, Kocaeli Üniversitesi, 2018

Health&Medicine, Teorik ve Uygulamalı Fitoterapi Eğitimi, Biruni Üniversitesi, 2018

Health&Medicine, Biyoinformatik Kursu, Kocaeli Üniversitesi, 2018
Occupational Health and Safety, İş Sağlığı ve Güvenliği Eğitimleri, İstanbul Üniversitesi, 2014
Health&Medicine, Deney Hayvanları Kullanım Sertifikası, İstanbul Üniversitesi, 2012
Health&Medicine, Moleküller ve Translasyonel Onkoloji Kursu, Tıbbi Onkoloji Derneği, 2011

Dissertations

Doctorate, Prostat Kanserli Hastalarda FMNL1 ve PAK1 Seviyelerinin Belirlenmesi, İstanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2021
Postgraduate, Prostat Kanserli Hastalarda "EMMPRIN" ve "ADAM12" Düzeyleri, İstanbul University, Health Sciences Institute, Temel Onkoloji Anabilim Dalı/Kanser Biyokimyası Programı, 2013

Research Areas

Medicine, Health Sciences, Fundamental Medical Sciences, Biochemistry, Internal Medicine Sciences, Internal Diseases , Oncology, Life Sciences, Biochemistry, Molecular Biochemistry, Natural Sciences

Academic Titles / Tasks

Research Assistant PhD, İstanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2013 - Continues

Academic and Administrative Experience

Birim Tehlikeli Madde Sorumlusu, İstanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2020 - 2023
Tİbbi Cihaz Sorumlusu, İstanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2018 - 2023
Hastane Afet ve Acil Durum Planı Hazırlama Komisyonu, İstanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2018 - 2023
Tesis Güvenliği Komitesi, İstanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2017 - 2023
Tehlikeli Madde Yönetimi, İstanbul University, Onkoloji Enstitüsü, Temel Onkoloji Ana Bilim Dalı, 2019 - 2020

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Clinical significance of serum membrane-bound mucin-2 levels in breast cancer**
Bademler S., ZİRTİLOĞLU A., Sari M., Ucuncu M. Z., Dogru E., Karabulut S.
Biomolecules, vol.9, no.2, 2019 (SCI-Expanded)
- II. **Can DCLK1 be a biomarker for head and neck cancer?**
Yasasever C., Dogru E., Serilmez M., Ahmet K., Karaman S.
FEBS OPEN BIO, vol.8, pp.318, 2018 (SCI-Expanded)
- III. **Clinical Significance of Serum Ykl-40 (Chitinase-3-Like-1 Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients**
Erturk K., Tas F., Serilmez M., Bilgin E., Yasasever V.
Asian Pacific journal of cancer prevention : APJCP, vol.18, pp.1383-1387, 2017 (SCI-Expanded)
- IV. **Clinical Significance of Circulating Serum Cellular Heat Shock Protein 90 (HSP90) Level in Patients with Cutaneous Malignant Melanoma**
Tas F., Bilgin E., Erturk K., Duranyıldız D.
Asian Pacific journal of cancer prevention : APJCP, vol.18, pp.599-601, 2017 (SCI-Expanded)
- V. **CIRCULATING MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1/CCL-2) AS A POTENTIAL**

BIMARKER FOR THE DIAGNOSIS OF PANCREATIC ADENOCARCINOMA

Afsar C. U., Karabulut M., Karabulut S., Alis H., Binboga S., Bilgin E., Aykan N. F.

ACTA MEDICA MEDITERRANEA, vol.33, no.3, pp.501-507, 2017 (SCI-Expanded)

VI. Clinical significance of serum interleukin-17 levels in colorectal cancer patients

Karabulut S., Afsar C. U., Karabulut M., Kilic L., Alis H., Kones O., Bilgin E., Aykan N. F.

JOURNAL OF BUON, vol.21, no.5, pp.1137-1145, 2016 (SCI-Expanded)

VII. Clinical significance of serum claudin-1 levels in melanoma patients

Tas F., Bilgin E., Erturk K., Duranyildiz D.

MELANOMA RESEARCH, vol.26, no.4, pp.377-381, 2016 (SCI-Expanded)

VIII. Serum leptin levels may have diagnostic and predictive roles in patients with pancreatic adenocarcinoma treated with gemcitabine-based chemotherapy.

Karabulut S., AFSAR C. U., KARABULUT M., ALIS H., Erturk K., Karaman S., KONES O., Bilgin E., Tas F.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.21, no.4, pp.895-902, 2016 (SCI-Expanded)

IX. Circulating serum levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and larynx carcinoma patients

Guveli M. E., Duranyildiz D., Karadeniz A., Bilgin E., Serilmez M., Soydinc H. O., Yasasever V.

TUMOR BIOLOGY, vol.37, no.7, pp.8979-8983, 2016 (SCI-Expanded)

X. Serum activated leukocyte cell adhesion molecule and intercellular adhesion molecule-1 in patients with gastric cancer: Can they be used as biomarkers?

Erturk K., Tastekin D., Bilgin E., Serilmez M., Bozbey H. U., Sakar B.

BIOMEDICINE & PHARMACOTHERAPY, vol.77, pp.86-91, 2016 (SCI-Expanded)

XI. CIRCULATING MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (MIP1-A) AS A POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PATIENTS WITH PANCREATIC ADENOCARCINOMA

Karabulut S., Afsar C. U., Karabulut M., Alis H., Binboga S., Ozkara I. O., Karaca F., Bilgin E., Tas F.

ACTA MEDICA MEDITERRANEA, vol.32, no.4, pp.1035-1040, 2016 (SCI-Expanded)

XII. Clinical significance of serum protease activated receptor1 levels in patients with lung cancer

Erturk K., Tastekin D., Bilgin E., Tas F., Disci R., Duranyildiz D.

European Review for Medical and Pharmacological Sciences, vol.20, no.2, pp.243-249, 2016 (SCI-Expanded)

XIII. Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer

Erturk K., Tastekin D., Serilmez M., Bilgin E., Bozbey H. U., Vatansever S.

TUMOR BIOLOGY, vol.37, no.1, pp.405-412, 2016 (SCI-Expanded)

XIV. Androgen Stimulation of PCA3 and miR-141 and Their Release from Prostate Cancer Cells

Gezer U., Tiryakioglu D., Bilgin E., Dalay N., Holdenrieder S.

CELL JOURNAL, vol.16, no.4, pp.488-493, 2015 (SCI-Expanded)

XV. Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer

Tas F., Bilgin E., Karabulut S., Duranyildiz D.

CYTOKINE, vol.71, no.1, pp.66-70, 2015 (SCI-Expanded)

XVI. EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study

Dogru E., Dizdar Y., Aksit E., Ural F., Sanli O., Yasasever V.

TUMOR BIOLOGY, vol.35, no.11, pp.11647-11653, 2014 (SCI-Expanded)

XVII. Clinical significance of serum fibronectin and vitronectin levels in melanoma patients

Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.

MELANOMA RESEARCH, vol.24, no.5, pp.475-479, 2014 (SCI-Expanded)

XVIII. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer

Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.

TUMOR BIOLOGY, vol.35, no.9, pp.9303-9309, 2014 (SCI-Expanded)

XIX. Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy

- Tas F., Karabulut S., Bilgin E., Duranyildiz D.
TUMOR BIOLOGY, vol.35, no.8, pp.7871-7875, 2014 (SCI-Expanded)
- XX.** **Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma.**
Tas F., Karabulut S., Bilgin E., Kilic L., Ciftci R., Duranyildiz D.
Journal of gastrointestinal cancer, vol.44, pp.404-9, 2013 (SCI-Expanded)
- XXI.** **Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma**
Tas F., Karabulut S., Bilgin E., Sen F., Yildiz I., Tastekin D., Ciftci R., Duranyildiz D.
TUMOR BIOLOGY, vol.34, no.6, pp.3529-3536, 2013 (SCI-Expanded)
- XXII.** **Serum M65 as a Biomarker for Metastatic Renal Cell Carcinoma**
Yildiz I., Sen F., Kilic L., Keskin S., Duranyildiz D., Bilgin E., Disci R., Ekenel M., Darendeliler E., Bavbek S., et al.
CLINICAL GENITOURINARY CANCER, vol.11, no.3, pp.290-296, 2013 (SCI-Expanded)
- XXIII.** **Clinical and Prognostic Significance of Coagulation Assays in Advanced Epithelial Ovarian Cancer**
Tas F., Kilic L., Bilgin E., Keskin S., Sen F., Ciftci R., Yildiz I., Yasasever V.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.23, no.2, pp.276-281, 2013 (SCI-Expanded)
- XXIV.** **For Which Cancer Types can Neuron-Specific Enolase be Clinically Helpful in Turkish Patients?**
Bilgin E., Dizdar Y., Serilmez M., Soydinc H. O., Yasasever C., Duranyildiz D., Yasasever V.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.4, pp.2541-2544, 2013 (SCI-Expanded)
- XXV.** **Clinical and prognostic significance of coagulation assays in melanoma**
Tas F., Ciftci R., Kilic L., Bilgin E., Keskin S., Sen F., Yildiz I., Yasasever V.
MELANOMA RESEARCH, vol.22, no.5, pp.368-375, 2012 (SCI-Expanded)
- XXVI.** **Markers of Bone Metastases in Breast and Lung Cancers**
Bilgin E., Yasasever V., Soydinc H. O., Yasasever C., Ozturk N., Duranyildiz D.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.9, pp.4331-4334, 2012 (SCI-Expanded)

Articles Published in Other Journals

- I. **Significance of serum neural precursor cell-expressed developmentally downregulated protein 9 in melanoma**
Erturk K., Tas F., Serilmez M., Bilgin E., Duranyildiz D.
MOLECULAR AND CLINICAL ONCOLOGY, vol.8, no.1, pp.204-208, 2018 (ESCI)
- II. **Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer.**
KARABULUT M., AFSAR C., ALIS H., ORAN E., KARABULUT S., AKARSU C., SAHBAZ N. A., GÜMÜSOGLU A. Y., Bilgin E., AYKAN N. F.
Molecular and clinical oncology, vol.7, pp.787-797, 2017 (ESCI)
- III. **Clinical significance of serum laminin and type-IV collagen levels in cutaneous melanoma patients**
Tas F., Bilgin E., Karabulut S., Duranyildiz D.
MOLECULAR AND CLINICAL ONCOLOGY, vol.5, no.1, pp.195-200, 2016 (ESCI)
- IV. **Clinical significance of serum protease-activated receptor 1 (PAR1) level in patients with breast cancer**
Ciftci R., Taş F., Bilgin E., Keskin S., Yildiz I., Duranyildiz D., Saip P., Karanlik H., Vatansever S.
Journal of Oncological Science, vol.2, no.1, pp.7-11, 2016 (Peer-Reviewed Journal)
- V. **Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients.**
Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.
Journal of gastrointestinal cancer, vol.47, pp.182-6, 2016 (Scopus)
- VI. **Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma**
Tas F., Bilgin E., Karabulut S., Erturk K., Duranyildiz D.
BBA CLINICAL, vol.5, pp.166-169, 2016 (ESCI)
- VII. **Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer**

- Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.
BIOMEDICAL REPORTS, vol.4, no.5, pp.609-614, 2016 (ESCI)
- VIII. **Clinical significance of serum laminin levels in patients with lung cancer**
Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.
BIOMEDICAL REPORTS, vol.4, no.4, pp.485-488, 2016 (ESCI)
- IX. **Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome**
Tas F., Bilgin E., Karabulut S., Tastekin D., Duranyildiz D.
MOLECULAR AND CLINICAL ONCOLOGY, vol.4, no.4, pp.655-659, 2016 (ESCI)
- X. **Pankreas adenokarsinomlu hastalarda serum transforme edici büyümeye factor beta 1 TGF B1 düzeyleri**
KARABULUT S., KARABULUT M., AFŞAR USUL Ç., ALIŞ H., DAĞOĞLU N., AKARSU C., ERTÜRK K., BİLGİN E., TAŞ F.
İstanbul Tip Fakültesi Dergisi, vol.79, no.1, pp.9-15, 2016 (Peer-Reviewed Journal)
- XI. **SERUM TRANSFORMING GROWTH FACTOR BETA 1 (TGF-B1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS**
Karabulut S., Karabulut M., Usul Afsar C., Alis H., Dagoglu N., Akarsu C., Erturk K., Bilgin E., Tas F.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.79, no.1, pp.9-15, 2016 (ESCI)
- XII. **PANKREATİK ADENOKANSERDE SİRKÜLASYONDAKİ PROİNFLAMATUAR SİTOKİN DÜZEYLERİNİN KLINİK ÖNEMİ**
KARABULUT S., KARABULUT M., USUL AFŞAR Ç., ALIŞ H., GÜVELİ M. E., ÜNSAL M. G., AYDOĞAN F., BİLGİN DOĞRU E.
İSTANBUL TIP FAKÜLTESİ DERGİSİ, vol.78, no.4, pp.102-109, 2015 (Peer-Reviewed Journal)
- XIII. **CLINICAL SIGNIFICANCE OF CIRCULATING PROINFLAMMATORY CYTOKINE LEVELS IN PATIENTS WITH PANCREATIC ADENOCARCINOMA**
Karabulut S., Karabulut M., Afsar C. U., Alis H., Guveli M. E., Unsal M. G., Aydogan F., Bilgin E., Tas F.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.78, no.4, pp.102-109, 2015 (ESCI)
- XIV. **miR-141 and miR-375 induction and release are different from PSA mRNA and PCA3 upon androgen stimulation of LNCaP cells.**
TIRYAKIOGLU D., Bilgin E., HOLDENRIEDER S., DALAY N., GEZER U.
Biomedical reports, vol.1, pp.802-806, 2013 (ESCI)
- XV. **Küçük Hücreli Akciğer Kanserinde Anjiogenik Faktörler (VEGF, VEGFR-1, VEGFR-2)**
OĞUZ SOYDİNÇ H., DURANYILDIZ D., BİLGİN E., TAŞ F., YASASEVER V.
TÜRK ONKOLOJİ DERGİSİ, vol.27, no.2, pp.55-61, 2012 (Scopus)
- XVI. **Angiogenic factors in small cell lung cancer (VEGF, VEGFR-1, VEGFR-2)**
OĞUZ SOYDİNÇ H., DURANYILDIZ H. D., Bilgin E., TAŞ F., Yasasever V.
TÜRK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.27, no.2, pp.55-61, 2012 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

- I. **Prognostic Importance of BRAF and PTEN Proteins in Patients with Malignant Melanoma**
Bilgin Doğru E., Tilgen Yasasever C., Serilmez M., Taş F., Duranyıldız H. D., Oğuz Soydinpç H.
IX. INTERNATIONAL CONGRESS OF MOLECULAR MEDICINE "MOLECULAR MEDICINE IN LIFE SCIENCES", İstanbul, Turkey, 18 - 20 December 2023, pp.1
- II. **Importance of AXL Molecule in Lung Cancers**
Kizir A., Bilgin Doğru E., Tilgen Yasasever C., Serilmez M.
15. İstanbul Üniversitesi Onkoloji Enstitüsü Günleri Sempozyumu ve 8. İstanbul Üniversitesi Onkoloji Enstitüsü Çalıştayı, İstanbul, Turkey, 1 - 02 December 2017, pp.1
- III. **MEME KANSERİ TANILI HASTALARDA 25(OH)D VİTAMİNİ DÜZEYLERİ**

- HATİBOĞLU S., BİLGİN E., TİLGEN YASASEVER C., SALMAYENLİ N.
Klinik Biyokimya Uzmanları Derneği Uluslararası Katılımlı Kongre Lab Expo 2017, 1 - 05 October 2017
- IV. **Over Kanserinde HMGB1 ve IRE1'in Önemi**
BİLGİN DOĞRU E., TİLGEN YASASEVER C., SERİLMEZ M., SAİP P. M., YASASEVER F. V.
22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.159
- V. **Meme Kanserli Hastalarda TIMP-1, HA ve SPARC Düzeyleri**
Tilgen Yasasever C., Bilgin Doğru E., Serilmez M., Öztürk N., Yasasever F. V.
22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.162
- VI. **Clinical significance of caveolin-1 and fibronectin in pancreatic cancer**
Dogru E., Yasasever C., Serilmez M., Dagoglu N., Yasasever V.
ECCO European Cancer Congress, Amsterdam, Netherlands, 27 - 30 January 2017, vol.72
- VII. **Serum caveolin-1 and fibronectin levels as clinical markers for patients with malignant melanoma**
Yasasever C., Dogru E., Serilmez M., Tas F., Yasasever V.
ECCO European Cancer Congress, Amsterdam, Netherlands, 27 - 30 January 2017, vol.72
- VIII. **The biological role of AKT serine/threonine kinase 2 in lung cancer**
Serilmez M., Karaman S., Soydinc H. O., Yasasever C., Bilgin E., Duranyıldız D., Yasasever V.
ECCO European Cancer Congress, Amsterdam, Netherlands, 27 - 30 January 2017, vol.72
- IX. **Mide Kanserinde Serum Interleukin-29, Interleukin-32 ve Tumor Necrosis Factor Alpha'nın Klinik Önemi**
ERTÜRK K., TAŞTEKİN D., SERİLMEZ M., BİLGİN DOĞRU E., H. U., VATANSEVER S.
3. Ulusal İmmüno-Onkoloji ve Hedefe Yönelik Kanser Tedavileri Kongresi, Antalya, Turkey, 11 - 15 May 2016, pp.1
- X. **Circulating interleukin-18 (IL-18) as a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.**
Afsar C. U., Karabulut M., KARABULUT S., Tuna S., Alis H., Gonenc M., Dagoglu N., Bilgin E., TAŞ F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- XI. **OMENTIN LEVELS IN COLON CANCER**
Serilmez M., Ciftci R., BİLGİN DOĞRU E., DURANYILDIZ H. D.
IFCC WorldLAB İstanbul 2014, İstanbul, Turkey, 22 - 26 June 2014, pp.464
- XII. **DO THE MATRIX METALLOPROTEASES HAVE ANY EFFECT ON EPITHELIAL OVARIAN TUMORS?**
BİLGİN DOĞRU E., Serilmez M., ÖZTÜRK N., DURANYILDIZ H. D., YASASEVER F. V.
IFCC WorldLAB İstanbul 2014, İstanbul, Turkey, 22 - 26 June 2014, pp.371
- XIII. **Meme Kanserli Hastalarda Serum MIF (Macrophage Migration Inhibitory Factor) Düzeylerinin Klinik Açıdan Önemi**
Ciftci R., Karabulut S., TİLGEN YASASEVER C., Aksit E., Yıldız I., BİLGİN DOĞRU E., Tas F., Vatansever S., Keskin S., VATANSEVER S., et al.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.501
- XIV. **Significance of NSE in various cancer types**
Bilgin E., Soydinc H. O., Yasasever C. T., Serilmez M., Yasasever V.
22nd IUBMB Congress/37th FEBS Congress, Sevilla, Spain, 4 - 09 September 2012, vol.279, pp.101
- XV. **Leptin levels in breast cancer**
Serilmez M., Soydinc H. O., Bilgin E., Yasasever C., Duranyıldız D.
22nd IUBMB Congress/37th FEBS Congress, Sevilla, Spain, 4 - 09 September 2012, vol.279, pp.101-102
- XVI. **Akciğer kanserinde koagülasyon testlerinin prognostik önemi**
KILIC L., YILDIZ İ., ŞEN F., EKENEL M., KESKİN S., BİLGİN DOĞRU E., DURANYILDIZ D., TAŞ F.
4. Tibbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.150-151
- XVII. **İleri evre kolon kanserli hastalarda serum adiponektin düzeyleri**
serilmez m., BİLGİN DOĞRU E., TİLGEN YASASEVER C., Duranyıldız D., YASASEVER F. V.
3. DETAE Günleri, İstanbul, Turkey, 17 - 18 November 2011, pp.74
- XVIII. **Angiogenesis markers in nasopharynx and larynx cancers**
Serilmez M., Bilgin E., Yasasever V., Duranyıldız D.

- 36th FEBS Congress of the Biochemistry for Tomorrows Medicine, Torino, Italy, 25 - 30 June 2011, vol.278, pp.233
- XIX. **What kind of a role may play IFN-gamma and emmprin in head and neck cancers?**
Bilgin E., Serilmez M., Duranyildiz D., Yasasever V.
36th FEBS Congress of the Biochemistry for Tomorrows Medicine, Torino, Italy, 25 - 30 June 2011, vol.278, pp.197
- XX. **Baş-Boyun kanserlerinde EMMPRIN'in önemi**
BİLGİN E., DURANYILDIZ H. D., Serilmez M., ŞEN F., YASASEVER F. V.
19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.1
- XXI. **Baş-Boyun kanserlerinde VEGF-C'nin yeri var mı?**
Serilmez M., BİLGİN E., KARADENİZ A. N., Yıldız I., YASASEVER F. V.
19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.1

Supported Projects

DURANYILDIZ H. D., BİLGİN DOĞRU E., YASASEVER F. V., Project Supported by Higher Education Institutions, Prostat Kanserli Hastalarda FMNL1 ve PAK1 Seviyelerinin Belirlenmesi, 2017 - 2021

VATANSEVER S., BADEMLER S., TİLGEN YASASEVER C., KARANLIK H., SERİLMEZ M., BİLGİN DOĞRU E., Project Supported by Higher Education Institutions, Meme Tümörlerinde Nektin2 ve Nektin4 Adezyon Molekülleri, 2017 - 2019

KARANLIK H., TİLGEN YASASEVER C., SERİLMEZ M., BİLGİN DOĞRU E., BADEMLER S., OĞUZ SOYDİNÇ H., Project Supported by Higher Education Institutions, Meme Tümörlerinde Tensin2 Molekülü, 2017 - 2018

KİZİR A., SERİLMEZ M., BİLGİN DOĞRU E., TİLGEN YASASEVER C., ERTÜRK K., Project Supported by Higher Education Institutions, Akciğer Kanserlerinde AXL Molekülü, 2017 - 2018

KARADENİZ A. N., SERİLMEZ M., KARAMAN Ş., TİLGEN YASASEVER C., BİLGİN DOĞRU E., Project Supported by Higher Education Institutions, Baş-Boyun Kanserlerinde DCLK1 Molekülü, 2017 - 2018

BADEMLER S., SERİLMEZ M., BİLGİN DOĞRU E., KARANLIK H., TİLGEN YASASEVER C., Project Supported by Higher Education Institutions, Meme Kanserinde CPA4 Seviyesinin Belirlenmesi ve Önemi, 2017 - 2018

Scientific Refereeing

GROWTH FACTORS, SCI Journal, November 2022
BMC CANCER, Journal Indexed in SCI-E, May 2022
BMC CANCER, Journal Indexed in SCI-E, February 2022
BIOMARKERS, SCI Journal, November 2021
BIOMARKERS, SCI Journal, October 2021
BMC CANCER, Journal Indexed in SCI-E, October 2021
BIOMARKERS, SCI Journal, October 2021
Biomarkers, SCI Journal, June 2018
Tumor Biology, National Scientific Refreed Journal, December 2015

Metrics

Publication: 63
Citation (WoS): 244
Citation (Scopus): 291
H-Index (WoS): 10
H-Index (Scopus): 11

Congress and Symposium Activities

- İşbirliği Toplantıları-V, Audience, İstanbul, Turkey, 2023
- XXV. IFCC-EFLM EuroMedLab Congress (hybrid), Audience, Rome, Italy, 2023
- Ulusal Kanser Haftası Farkındalık Arttırma Sempozyumu, Audience, İstanbul, Turkey, 2023
- İ.Ü. Onkoloji Enstitüsü Günleri, Audience, İstanbul, Turkey, 2023
- Critical Role of Clinical Laboratories in the Covid-19 Pandemic, Audience, Milan, Italy, 2021
16. Ulusal Onkolojik Araştırmalar Web Çalıştayı, Audience, İstanbul, Turkey, 2021
18. İSTANBUL ÜNİVERSİTESİ ONKOLOJİ ENSTİTÜSÜ GÜNLERİ "Dünyada Klinik Uygulamaları Etkileyen Çalışmalar" Çevrimiçi sempozyum, Audience, İstanbul, Turkey, 2020
- XII. Aziz Sancar DETAЕ Günleri "COVID-19: Moleküller ve Klinik Yaklaşım", Audience, İstanbul, Turkey, 2020
- Temel Onkoloji Derneği Çevrimiçi Bilim Günü, Audience, İstanbul, Turkey, 2020
1. Temel Onkoloji Sempozyumu, Attendee, Turkey, 2018
1. Biyometroloji ve Moleküller Biyoloji Çalıştayı, Attendee, Kocaeli, Turkey, 2018
- ECCO 2017 - European Cancer Congress, Attendee, Amsterdam, Netherlands, 2017
- TÜBİTAK 1000 Projeleri AR-GE Strateji Çalıştayı, Audience, İstanbul, Turkey, 2016
- Sabancı Üniversitesi Karaköy Otofaji Sempozyumu, Attendee, İstanbul, Turkey, 2014
1. Moleküller Üroloji Toplantısı, Attendee, İstanbul, Turkey, 2014
- IFCC-WorldLab - 22nd International Congress of Clinical Chemistry and Laboratory Medicine, Attendee, İstanbul, Turkey, 2014
- 22nd IUBMB & 37th FEBS Congress, Attendee, Sevilla, Spain, 2012
3. DETAЕ Günleri, Attendee, İstanbul, Turkey, 2011
- 36th FEBS Congress, Attendee, Torino, Italy, 2011
19. Ulusal Kanser Kongresi, Invited Speaker, Antalya, Turkey, 2011
- Türk Biokimya Derneği Proteomik Araştırmaları Temel Bilgiler ve Uygulama Örnekleri Toplantısı, Attendee, İstanbul, Turkey, 2009